N/A N=11 Magnetic Resonance Imaging Using Innovative Pulse Sequences
Clinical Indication for a Head MRI
Primary: Number of Head Images Successfully Collected — 10 Images
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 Magnetic Resonance Imaging Study of Geriatric Depression
Major Depressive Disorder
Primary: HAM-D 17 (Hamilton Depression Rating Scale) — 1.0; 18.5 Units on a scale
N/A N=189 Comparative Study of Conventional MR Images With Synthetically Reconstructed MR Images of the Brain
Clinical Indication for Brain MRI · Healthy Volunteers
Primary: Sensitivity of Pathological Findings (Full Analysis Set) — 0.66; 0.68 Proportion of participants
N/A N=14 MR Fingerprinting: A Novel Sequence Applied to Neuroimaging
Disease;Neurological
Primary: Percent of Participants With Visible Region of Interest (Imaging Visibility) — 100 percentage of participants
N/A N=16 Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)
Lung Cancer
Primary: Number of Participants Whose Tumor Position is Visible Within ~2mm Using Cine-MRI Scans and External Sensors — 7 participants
N/A N=38 An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio
N/A N=208 MRI Based Active Selection for Treatment Trial
Prostate Cancer
Primary: Rate of Disease Progression Within the First Two Surveillance Biopsies — 36.1 percentage of participants
N/A N=15 Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
N/A N=212 Quantitative Automated Lesion Detection of Traumatic Brain Injury
Traumatic Brain Injury
Primary: Performance on Trail-making Test, Part B — -0.02; 0.18 z-score — p=< 0.04
N/A N=477 Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2
Concussion · Traumatic Brain Injury
Primary: MRI Image Data Sets — 79; 150; 290; 111 Images collected
N/A N=21 Magnetic Resonance Imaging (MRI) of Appendicitis in Children
Appendicitis
Primary: Diagnostic Sensitivity/Specificity and Accuracy of Appendiceal MRI Comparedsurgical Findings or Clinical Follow-up — 13; 17; 4; 19 participants
N/A N=239 ENABLE MRI (Magnetic Resonance Imaging)
Magnetic Resonance Imaging
Primary: Percentage of Participants Free From MR (Magnetic Resonance) Scan-related Complications — 100 percentage of participants
N/A N=22 Novel MRI Sequence- MR Fingerprinting
Disease
Primary: Percent of Patients With Visible Region of Interest (Imaging Visibility)
N/A N=92 MRI Assessing Clinical Usability of STrategically Acquired Gradient Echo on Human Participants
MRI
Primary: Numeric Rating Scale of Clinical Usability Assessment of STAGE Outputs — 49; 40; 0; 0 Participants
N/A N=6 Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent
Meniere's Disease
Primary: Vestibular "Endolymphatic Hydrops (EH)" — 0; 4; 2 participants
N/A N=148 A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
Brain Cancer
Primary: Number of Participants Who Received PET/CT and MRI Perfusion Studies — 53; 95 Participants
N/A N=63 China 3T MRI Study
Bradycardia · Tachycardia · Heart Failure
Primary: The Occurrence of an MRI-related Event for CIED — 59; 0 Participants — p=0.002
N/A N=33 Neuroimaging in Patients Undergoing TMS for Depression
Treatment Resistant Depression
Primary: Change in Functional Connectivity Measured by Resting MRI — 0.103399365; -0.7637409 correlation coefficients
N/A N=386 Clinical Use of a Neonatal MRI System
NICU MRI
Primary: Number of Participants With Adverse Events as Observed During and After Scanning. — 0 Participants
N/A N=45 MRI for Non-Invasive Imaging in Neonates and Children
Healthy · Cystic Fibrosis (CF) · Asthma
Primary: Ventilation Defects as Seen on Hyperpolarized Helium-3 MRI — 9; 13; 16 Participants
N/A N=1,509 Clinically Indicated Magnetic Resonance Imaging in Patients With Cardiac Devices
Arrhythmias, Cardiac
Primary: Device Malfunction — 24; 52 Participants
N/A N=57 Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study
Cervical Cancer
Primary: Number of Participants With Improved Image Quality in the Shifted Position — 0; 15 Participants
N/A N=117 Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR Images
Clinical Indication for Brain MRI
Primary: Mean Diagnostic Image Quality Difference Between Conventional Versus Synthetic MR Utilizing a 5 Point Likert Scale — -0.335 units on a 5-point scale — p=<0.001
N/A N=62 Clinical Evaluation of an Integrated PET/MRI System
Subjects With Clinical Indication for PET/CT
Primary: Number Usable PET/MRI Image Sets — 70 Usable image sets
N/A N=158 Advanced MRI Sequences for Radiation Therapy Treatment Planning
Cancer
Primary: Number of Participants Successfully Contributing MRI Data — 158 Participants
N/A N=657 Clinical Use of a New Neonatal MRI System
Magnetic Resonance Imaging
Primary: Number of Participants With Adverse Events as Observed During and After Scanning. — 4 Participants
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
N/A N=26 Sensory Effects of Rapidly-Changing Magnetic Fields
Sensory Disorders
Primary: Degree of Discomfort Under Applied Pulsed Magnetic Fields — 0 percentage of subjects with discomfort
N/A N=40 Imaging Biomarkers for TMS Treatment of Depression
Depression
Primary: Depressive Symptoms at 4 Weeks — 15.6; 15.6 units on a scale — p=0.16
Phase 2 N=57 Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Central Nervous System Pathology
Primary: Overall Diagnostic Preference — 10; 34; 56; 26 Percentage of participants — p=<0.0001